Key result
MDM2 and EGFR co-expression in pulmonary artery sarcoma is linked to ~12-month shorter PFS and metastasis.
Why the study?
Biomarker signatures and their relations with prognosis of pulmonary artery sarcoma patients are not well established, and potential diagnostic markers and molecular therapeutic targets are needed.
Cohort (n=16)
No
MDM2 expression and MDM2/EGFR co-expression are associated with shorter progression-free survival and tumor metastasis in patients with pulmonary artery sarcoma.
Answers are grounded in this paper and cite their sources.
May refine pulmonary artery sarcoma prognosis; leaves open targeted inhibition trials.
There are few studies investigating the biomarker signatures and their relations with prognosis of pulmonary artery sarcoma patients. In the present study, we performed a cohort study on 16 cases of pulmonary artery sarcoma in an attempt to identify the potential diagnostic markers and molecular therapeutic targets of that vascular sarcoma. Patients who had undergone pulmonary artery sarcoma tumorectomy over 7 ½ years in our hospital were enrolled in this retrospective study. The resected tumors were analyzed by histopathology, the expression and mutation of Murine Double Minute 2 (MDM2), Epidermal Growth Factor Receptor (EGFR), and Platelet-Derived Growth Factor Alpha (PDGFRA) by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The correlations between patients’ outcomes and tumor histological, IHC and FISH features were statistically analyzed. MDM2 immunostaining was seen mainly in intimal sarcoma. At univariate analysis, MDM2 expression had a positive correlation with shorter progression free survival (PFS). MDM2 and EGFR co-expression also had a positive correlation with shorter PFS and tumor metastasis. This study investigated MDM2, EGFR, and PDGFRA as potential biomarkers for diagnosis of pulmonary artery sarcoma and therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Bihong Zha (2021) conducted a cohort in Pulmonary artery sarcoma (n=16). MDM2 and EGFR co-expression vs. Lack of MDM2 and EGFR co-expression was evaluated on Progression free survival (PFS) in months (p=0.019). MDM2 and EGFR co-expression in pulmonary artery sarcomas was associated with a shorter progression-free survival and tumor metastasis.
Synapse has enriched 10 related papers. Consider them for comparative context: